Ascendis Pharma A/S
Business
Ascendis Pharma A/S is a global biopharmaceutical company that applies its proprietary TransCon technology platform to develop long-acting prodrug therapies addressing unmet medical needs. The company markets two approved products—YORVIPATH (TransCon PTH) for hypoparathyroidism and SKYTROFA (TransCon hGH) for growth hormone deficiency—and maintains a pipeline of clinical-stage candidates in Endocrinology Rare Disease and Oncology. Ascendis distributes products directly in the United States and select European countries, while leveraging partnerships with Teijin (Japan) and VISEN (Greater China) for geographic expansion, and collaborates with Novo Nordisk on metabolic disease applications.
Summary from 20-F filed 2026-02-11
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-228.03M |
| Total assets | $1.30B |
| Total liabilities | $1.47B |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Ascendis Pharma A/S's CIK number?
Ascendis Pharma A/S's SEC CIK number is 0001612042 (1612042). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Ascendis Pharma A/S's SEC filings?
All of Ascendis Pharma A/S's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.